Meridian Bioscience (VIVO) is having a Dividend Yield of 3.89% with the Annual cash Dividend per share of $0.8. The last quarter cash dividend per share pay out was $0.2. Meridian Bioscience has a 5 year average dividend yield of 4% and the stock has a Indicated annual dividend of $0.5. Meridian Bioscience (VIVO) formally announced its most recent dividend on January 25, 2017 with a Dividend per share of $0.13. The new indicated annual dividend based on announced dividend per share is $0.5. The dividend yield based on the forward looking indicated annual dividend is 3.89%. Meridian Bioscience (VIVO) has the most recent dividend payout ratio of 1.08 with a 5-year average payout ratio of 0.93. Companys change in pay out ratio when compared to the last 5 years average pay out ratio has been 0.15. The 5 year historical dividend growth of Meridian Bioscience (VIVO) is at the rate of 1.49% while the R-Squared dividend growth is 0.72. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
Meridian Bioscience Inc. (NASDAQ:VIVO) witnessed a decline in the market cap on Thursday as its shares dropped 0.78% or 0.1 points. After the session commenced at $12.9, the stock reached the higher end at $12.95 while it hit a low of $12.55. With the volume soaring to 564,081 shares, the last trade was called at $12.75. The company has a 52-week high of $21.49. The company has a market cap of $538 million and there are 42,202,397 shares in outstanding. The 52-week low of the share price is $10.75. Meridian Bioscience, Inc. has lost 0.39% in the last five trading days and dropped 24.26% in the last 4 weeks. Meridian Bioscience, Inc. has dropped 23.12% during the last 3-month period . Year-to-Date the stock performance stands at -27.26%.
Currently the company Insiders own 2.3% of Meridian Bioscience Inc. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 0.34% . Institutional Investors own 87.9% of Meridian Bioscience Inc. shares. During last six month period, the net percent change held by insiders has seen a change of 1.98%. Company has reported several Insider transactions to the SEC, on Feb 3, 2017, Melissa Lueke (CFO) purchased 4,000 shares at 12.59 per share price.On Jan 30, 2017, Lawrence Baldini (EVP, Pres Global Operations) purchased 4,000 shares at 12.70 per share price.On Dec 5, 2016, Vecheslav A Elagin (EVP, Research & Development) sold 7,883 shares at 17.30 per share price.
Meridian Bioscience Last issued its quarterly earnings results on Jan 25, 2017. The company reported $0.15 EPS for the quarter, missing the analyst consensus estimate by $ -0.05. Analyst had a consensus of $0.20. The company had revenue of $46.80 million for the quarter, compared to analysts expectations of $51.15 million. The companys revenue was down -.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.21 EPS.
Meridian is a fully integrated life sciences company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections.